CureVac (NASDAQ:CVAC) Sets New 52-Week High – Time to Buy?

CureVac (NASDAQ:CVAC)’s stock price reached a new 52-week high on Friday . The stock traded as high as $5.72 and last traded at $5.60, with a volume of 22916470 shares trading hands. The stock had previously closed at $4.07.

Wall Street Analysts Forecast Growth

CVAC has been the subject of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th. UBS Group reduced their target price on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th.

CureVac Stock Up 37.6%

The firm’s fifty day simple moving average is $3.70 and its two-hundred day simple moving average is $3.46. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 10.18 and a beta of 2.49.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $4.27 million. Sell-side analysts anticipate that CureVac will post 0.72 EPS for the current year.

Institutional Trading of CureVac

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. purchased a new position in shares of CureVac in the fourth quarter valued at approximately $66,000. Geode Capital Management LLC lifted its holdings in CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company’s stock worth $824,000 after buying an additional 22,491 shares during the last quarter. Northern Trust Corp boosted its holdings in CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after purchasing an additional 29,759 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of CureVac in the 4th quarter valued at $391,000. Finally, Two Sigma Advisers LP purchased a new position in shares of CureVac during the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.